Comparative effectiveness research (CER) is at the forefront of new cost-control efforts, according to a panel of experts. CER aims to evaluate both the clinical and cost-effectiveness of treatments through head-to-head trials, including preventive measures. And although CER promises important new clinical insights, no one doubts that rising health care costs are forcing payers and pro viders alike to think about driving value.